Marizyme (Marizyme) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Marizyme ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Marizyme's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Marizyme ROCE % Historical Data

The historical data trend for Marizyme's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme ROCE % Chart

Marizyme Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-3.72

-15.53

-19.91

-71.74

-188.95

Marizyme Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-10.39	-123.31	-4,543.31	-	-

Marizyme ROCE % Calculation

Marizyme's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-35.123	/	( ( (38.688 - 2.922)	+	(22.015 - 20.603) )	/ 2 )
	=	-35.123	/	( (35.766	+	1.412)	/ 2 )
	=	-35.123	/	18.589
	=	-188.95 %

Marizyme's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-8.256	/	( ( (22.015 - 20.603)	+	(21.57 - 25.848) )	/ 2 )
	=	-8.256	/	( ( 1.412	+	-4.278 )	/ 2 )
	=	-8.256	/	-1.433
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Marizyme (OTCPK:MRZM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Marizyme ROCE % Related Terms

Thank you for viewing the detailed overview of Marizyme's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marizyme (Marizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458

Website

https://www.marizyme.com

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

Executives

Braeden Lichti	10 percent owner	650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel	director	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart	director	5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross	officer: Vice President of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov	officer: Chief Financial Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel	director, officer: Chief Executive Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond	officer: Acting VP of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf	director	14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk	director	FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr	officer: Executive Vice President	4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl	director	448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk	officer: Chief Science Officer	1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar	officer: Chief Operating Officer	167 CARMELA COURT, JUPITER FL 33478